Phytomedicines (medicines derived from plants) for sickle cell disease

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Oniyangi, Oluseyi ^a   Cohall, Damian H ^b  

^a NATIONAL HOSPITAL   (Nigeria)

^b UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CIKLAVIT; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HYDROXYUREA; NICOSAN; NIPRISAN; PLACEBO; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; UREA; ANTISICKLING AGENT; PLANT EXTRACT;

ABDOMINAL DISTENSION; BLOOD TRANSFUSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; META ANALYSIS; OCULAR PRURITUS; PERIORBITAL SWELLING; PHASE 2 CLINICAL TRIAL (TOPIC); PIGEONPEA; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; SIDE EFFECT; SWELLING; SYSTEMATIC REVIEW; VOMITING; PHYTOTHERAPY;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MLCS; MLOWN;

EID: 84874800185     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004448.pub4     Document Type: Review

References (42)

1. Akinsulie AO, Temiye EO, Akanmu AS, Lesi FEA, Whyte CO. Clinical evaluation of extract of Cajanus cajan (Ciklavit) in sickle cell anaemia. Journal of Tropical Paediatrics 2005;51(4):200-5.
2. Fonnebo V. Indiginous Nigerian medicinal plants may be useful in the management of sickle-cell disorder [comment]. Focus on Alternative and Complementory Therapies 2002;7(2):146.
3. Wambebe C. Chemistry and clinical evaluation of NIPRISAN in patients with sickle cell anemia [abstract]. The National Sickle Cell Disease Program 30th Annual Meeting Conference Proceedings, Sept 2002. 2002:46.
4. Wambebe C, Khamofu H, Momoh JAF, Ekpeyong M, Audu BS, Njoku OS, et al.Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with sickle cell disorder. Phytomedicine 2001;8(4):252-61.
5. Wambebe CO, Bamgboye EA, Badru BO, Hadiza K, Momoh JA, Ekpeyong M, et al.Efficacy of NIPRISAN in the prophylactic management of patients with sickle cell disease. Current Therapeutic Research 2001;62(1):26-34.
6. Panigrahi HK, Kushawa H, Sharma SS. Treatment of sickle cell disorders by ayurvedic medicine. Ancient Science of Life 1997;17(1):15-22.
7. Adzu B, Garba M, Haruna A, Maman M, Wambebe C, Gamaniel K. Effect of niprisan on single oral dose pharmacokinetics of paracetamol in rats. European Journal of Drug Metabolism and Pharmacokinetics 2001;26(3):201-4.
8. Akojie FO, Fung LW. Antisickling activity of hydroxybenzoic acids in Cajanus cajan. Planta Medica 1992;58(4):317-20.
9. Al-Awamy BH. Evaluation of commonly used tribal and traditional remedies in Saudi Arabia. Saudi Medical Journal 2001;22(12):1065-8.
10. Alexander-Reindorf C, Nwaneri RU, Worrell RG, Ogbonna A, Uzoma C. The significance of gall stones in children with sickle cell anaemia. JAMA 1990;82(9):645-50.
11. Awodogan A, Wambebe C, Gamaniel K, Okogun JI, Orisadipe A, Akah PA. Acute and short-term toxicity of NIPRISAN in rats I: biochemical study. Journal of Pharmacological Research and Development 1996;1:39-45.
12. Davies SC, Oni L. The management of patients with sickle cell disease. BMJ 1997;315(7109):656-60.
13. Deeks JJ, Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The CochraneCollaboration, 2008. Available from www.cochrane-handbook.org.
14. Ekeke GI, Shode FO. The reversion of sickled cells by Cajanus cajan. Planta Medica 1985;1(6):504-7.
15. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
16. Fall AB, Vanhaelen-Fastre R, Vanhaelen M, Lo I, Toppet M, Ferster A, et al.In vitro antisickling activity of a rearranged limonoid isolated from Khaya senegalensis. Planta Medica 1999;65(3):209-12.
17. Fleming AF. The presentation, management and prevention of crisis in sickle cell disease in Africa. Blood Reviews 1989;3(1):18-28.
18. Gamaniel K, Amos S, Akah PA, Samuel BB, Kapu S, Olusola A, et al.Pharmacological Profile of NIPRD 94/002/1-0: A Novel Herbal Antisickling Agent. Journal of Pharmaceutical Research 1998;3(2):39-45.
19. Hickman M, Modell B, Greengross P, Chapman C, Layton M, Falconer S, et al.Mapping the prevalence of sickle cell and beta thalassaemia in England: estimating and validating ethnic-specific rates. British Journal of Haematology 1999;104(4):860-7.
20. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistence in meta-analyses. BMJ 2003;327(7414):557-60.
21. Julian PT Higgins and Douglas G Altman on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The CochraneCollaboration, 2008. Available from www.cochrane-handbook.org.
22. Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003427]
23. Honig GR, Farnsworth NR, Ferenc C, Vida LN. Evaluation of Fagara zanthyloides root extract in sickle cell anemia blood in vitro. Lloydia 1975;38(5):387-90.
24. Huang Y, Ananthakrishnan T, Eid JE. Hydroxyurea-induced splenic regrowth in an adult patient with severe hemoglobin SC disease. American Journal of Hematology 2003;74(2):125-6.
25. Iwu MM, Igboko AO, Onwubiko H, Ndu UE. Effect of cajaminose from Cajanus cajan on gelation and oxygen affinity of sickle cell haemoglobin. Journal of Ethnopharmacology 1988;23(1):99-104.
26. Iyamu EW, Turner EA, Asakura T. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. British Journal of Haematology 2002;118(1):337-43.
27. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
28. Jones AP, Davies S, Olujohungbe A. Hydroxyurea in sickle cell disease. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD002202]
29. Konotey-Ahulu FI. Malaria and sickle-cell disease. British Medical Journal 1971;2(5763):710-1.
30. Larmie ET, Poston L. The in vitro effects of griffonin and ouabain on erythrocyte sodium content obtained from normal subjects and sickle cell patients. Planta Medica 1991;57(2):116-8.
31. Medical University of South Carolina. Bias. http://www.musc.edu/dc/icrebm/bias.html (accessed 6th February 2006).
32. Nzewi E. Malevolent ogbanje: recurrent reincarnation or sickle cell disease?. Social Science and Medicine 2001;52(9):1403-16.
33. Ohnishi T, Ohnishi ST, Ogunmola GB. Green tea extract and aged garlic extract inhibit anion transport and sickle cell dehydration in vitro. Blood Cells, Molecules and Diseases 2001;27(1):148-57.
34. Ohnishi ST, Ohnishi T. In vitro effects of aged garlic extract and other nutritional supplements on sickle erythrocytes. Journal of Nutrition 2001;131(3s):1085S-92S.
35. Ogoda Onah J, Akubue PI, Okide GB. The kinetics of reversal of pre-sickled erythrocytes by the aqueous extract of Cajanus cajan seeds. Phytotherapy Research 2002;16(8):748-50.
36. Oniyangi O, Omari AAA. Malaria chemoprophylaxis in sickle cell disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003489.pub2]
37. Osoba OA, Adesanya SA, Durosimi MA. Effect of Zanthoxylum xanthyloides and some substituted benzoic acids on glucose-6-phosphate and 6-phosphogluconate dehydrogenases in HbSS red cells. Journal of Ethnopharmacology 1989;27(1-2):177-83.
38. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al.Mortality in sickle cell disease: life expectancy and risk factors for early death. New England Journal of Medicine 1994;330(23):1639-44.
39. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
40. Serjeant GR, Serjeant BE. Sickle Cell Disease. 3rd Edition. Oxford: Oxford University Press, 2001.
41. Verzar R, Petri G. Medicinal plants in Mozambique and their popular use. Journal of Ethnopharmacology 1987;19(1):67-80.
42. Oniyangi O, Cohall DH. Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database of Systematic Reviews 2010, Issue 10. [DOI: 10.1002/14651858.CD004448.pub3]